SN · story · 5 November
Smith & Nephew · 3 headlines from 3 outlets, on 5 November 2026.
The company confirmed a review of options for its orthopaedics business.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
The Times is the largest at 1.7, ahead of MarketScreener (−0.8). Interactive Investor is the lowest at −6.7. 2 of the 3 are below zero.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Interactive Investor | −6.7 |
| The Times | 1.7 |
| MarketScreener | −0.8 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Interactive Investor | 1 | −6.7 |
| The Times | 1 | +1.7 |
| MarketScreener | 1 | −0.8 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| −6.7 | Lowered outlook, though company still pursuing a transaction. |
| +1.7 | Company reportedly willing to consider a transaction for its orthopaedics division. |
| −0.8 | Company assessing strategic alternatives for orthopaedics, outcome uncertain. |
A short, free morning email on how the news treated Smith & Nephew: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.